Soleno Therapeutics Inc (SLNO) Stock Price, Quote & News

Company Profile

Soleno Therapeutics, Inc., biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is VYKAT XR, an extended-release tablets for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.

Industry: Biotechnology

Sector: Healthcare

Phone: 650 213 8444

Fax: 650 213 8383

Website: soleno.life

Address:

100 Marine Parkway, Suite 400, Redwood City, United States

Night_Owl_Biotech Apr. 24 at 1:57 AM

It appears analysts have updated their $NBIX analysts as NBIX analyst consensus before the $SLNO acquisition was announced is higher almost exactly by the revenue forecast SLNO management provided NBIX. The graph compares NBIX 10-year analyst consensus to the 10-year revenue forecast prepared by $HZNP mgmt/BOD & provided $AMGN when Amgen acquired HZNP for an enterprise value of $28.2B. NBIX's market cap is $13.1B while it appears NBIX's $2.6B cash balance at 12/31/26 was used to buy SLNO for an EV of $2.44B. NBIX management will, eventually, need to consider alternate strategies to enhance shareholder value because NBIX has not traded at revenue multiples consistent with its peers in at least 2 years. This is not investment advice. $XBI

0 · Reply

Night_Owl_Biotech Apr. 21 at 5:24 PM

$SLNO filed its Form 14D9 with the SEC yesterday that included, among other things, the revenue forecast prepared by SLNO mgmt/BOD & provided to $NBIX. We find the discrepancy between SLNO analyst consensus & SLNO mgmt/BOD to be stunning. This highlights the enormous risk relying on analyst consensus when guesstimating potential M&A exit valuations. Attached are screenshots of SLNO analyst consensus per Seeking Alpha as of the morning the acquisition was announced (4/6/26) and SLNO's 14D9 filing from yesterday. The 2nd attachment provides the differences by year between SLNO analyst consensus & the revenue forecast provided by SLNO mgmt/BOD. Note 5-year analyst estimates were 32% higher than SLNO mgmt/BOD. 10-year revenues were 50% higher. The flip side is it appears the $2.444B enterprise value paid was priced @ 0.70X 5-year revenues & 0.28X 10-year revenues. FWIW it's our experience peer comm'l-stage M&A exits are priced at 0.90 to 1.05X 5-year & 0.30 to 0.40X 10-year $XBI $IBB $PFE ?

1 · Reply

Dragonites Apr. 19 at 3:43 AM

$SLNO The acquisition centers on VYKAT™ XR (formerly DCCR), which was FDA-approved in March 2025 as the first treatment for hyperphagia (extreme hunger) in Prader-Willi syndrome (PWS).

0 · Reply

anachartanalyst Apr. 17 at 2:02 PM

$SLNO https://anachart.com/wp-content/uploads/ana_temp/1776434501_soc-img.jpg

0 · Reply

theoptionsplug Apr. 17 at 4:42 AM

THINGS TO WATCH, FRIDAY, 4/17/26 👁️ $ALLY $BA $SLNO $SPY $QQQ

0 · Reply

InvestKaki Apr. 12 at 12:00 AM

$SPX $NBIX $SLNO $INTC $XCORP https://www.investkaki.com/p/billion-dollar-milestone

0 · Reply

dennismccain Apr. 11 at 3:10 AM

$SLNO About five weeks ago I posted this comment (see below) about this biotech company because its stock that had recently showed up on my list of growth stocks at a reasonable price. I’ve never really been comfortable or successful investing in biotech stocks, so I passed on the idea. Unfortunately for me that was a bad idea. The company recently announced that it was being bought out by another company at a very nice premium. I bring this whole thing up because regardless of my personal biases, likes, and dislikes, that list continues to identify fast growing, yet undervalued, companies. In this case another company recognized that value that I ignored and bought out the entire company. If I had bought those shares my ROI would have been about 50% for holding the shares for just 5 weeks.

0 · Reply

Ooil Apr. 8 at 9:01 PM

$IFRX Have a look at $SLNO that back in 2022 was a $1 ticket, 2023 at $5 and early 2024 close to $50. Soleno just bought out in a $2.9B deal. Soleno had an exceptional P3 in an orphan disease and was heavily shorted. And we all know that InflaRx late breaker presentation in PG shows everything but futility and also orphan. Whats the new p value in PG again? How many shares shorted?

1 · Reply

NasdaqPulse Apr. 8 at 12:38 PM

$NBIX bofa after $SLNO deal model revenues in-line with current SLNO consensus (BofA FY26: $460MN, BofA peak: $1.4BN). Vykat XR contributes $36/sh and net cash now contributes -$2/sh (prev. $25/sh) to new $199 PT prev. $190) 👉Click to view @NasdaqPulse for timely updates amid the volatility.

0 · Reply

BiotechGoldenEra Apr. 8 at 5:51 AM

$SLNO see you at 75

0 · Reply

Folia Health Launches “BRAVE-PWS” Study to Better Understand the Real-World Experience of Prader-Willi Syndrome Caregivers

Apr 15, 2026, 7:59 AM EDT - 9 days ago

Are TERN, SLNO, WSR Obtaining Fair Deals for their Shareholders?

TERN WSR

Apr 9, 2026, 8:23 AM EDT - 15 days ago

SOLENO THERAPEUTICS, INC. (SLNO) DEADLINE ALERT Bernstein Liebhard LLP Reminds Soleno Therapeutics, Inc. Investors of Upcoming Deadline

Apr 7, 2026, 1:17 PM EDT - 17 days ago

Soleno withdraws EU rare disease drug application ahead of Neurocrine takeover

NBIX

Apr 6, 2026, 7:34 AM EDT - 18 days ago

Neurocrine to Buy Soleno for $2.9 Billion

NBIX

Apr 6, 2026, 7:07 AM EDT - 18 days ago

Neurocrine to buy Soleno Therapeutics for $2.9 billion

NBIX

Apr 6, 2026, 7:00 AM EDT - 18 days ago

Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio

NBIX

Apr 1, 2026, 3:43 PM EDT - 23 days ago

Soleno (SLNO) Sued After DCCR Launch Setback, Share Drop-- Hagens Berman

Mar 31, 2026, 2:43 PM EDT - 24 days ago

SLNO Stockholders Have Rights – If You Lost Money Investing in Soleno Therapeutics, Inc. Contact Robbins LLP for Information About Recovering Your Losses

Mar 13, 2026, 6:28 PM EDT - 6 weeks ago

Notice to Long-Term Investors of Soleno Therapeutics, Inc. (SLNO): Grabar Law Office Investigates Claims on Your Behalf

Mar 12, 2026, 9:00 AM EDT - 6 weeks ago

SLNO Lawsuit Alleges Allegedly Conducting Sham Clinical Trials - Soleno Therapeutics, Inc. Investors Face Losses Following Allegedly Conducting Sham Clinical Trials: SueWallSt

Feb 25, 2026, 4:01 PM EST - 2 months ago

Soleno Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Update on U.S. Launch of VYKAT™ XR

Jan 5, 2026, 8:00 AM EST - 3 months ago

Soleno Therapeutics Announces Publication of Results from Pivotal Study of VYKAT™ XR in the Journal of Clinical Endocrinology and Metabolism

Dec 16, 2025, 12:21 PM EST - 4 months ago

Johnson Fistel Begins Investigation on Behalf of Soleno Therapeutics, Inc. (SLNO) Shareholders Who Have Incurred Losses

Dec 3, 2025, 4:05 PM EST - 5 months ago

Soleno Therapeutics Announces the Passing of Board Member William G. Harris

Nov 13, 2025, 12:17 PM EST - 5 months ago

Soleno Therapeutics (SLNO) Faces Investor Scrutiny Amid Disappointing VYKAT XR Starts, Discontinuations; Shares Down 26% – Hagens Berman

Nov 12, 2025, 10:56 AM EST - 5 months ago

Soleno Therapeutics, Inc. Investigated by the Portnoy Law Firm

Nov 11, 2025, 7:00 AM EST - 5 months ago

Soleno Therapeutics Announces Entry Into $100 Million Accelerated Share Repurchase Agreement

Nov 7, 2025, 10:04 AM EST - 6 months ago

Soleno Therapeutics (SLNO) Faces Investor Scrutiny Amid Disappointing VYKATÔ XR Starts, Discontinuations; Shares Down 26% -- Hagens Berman

Nov 4, 2025, 4:01 PM EST - 6 months ago

Soleno Therapeutics Reports Third Quarter 2025 Financial Results and Provides Update on U.S. Launch of VYKAT(TM) XR

Oct 28, 2025, 8:00 AM EDT - 6 months ago

Soleno Therapeutics to Participate in Upcoming November Conferences

Oct 9, 2025, 1:47 PM EDT - 7 months ago

Soleno Therapeutics (SLNO) Drops Amid Critical Scorpion Report -- Hagens Berman

Oct 9, 2025, 12:35 PM EDT - 7 months ago

SOLENO (SLNO) REMINDER: Bragar Eagel & Squire, P.C. Reminds Investors of the Investigation into Soleno Therapeutics, Inc. and Encourages Investors to Contact the Firm

Sep 10, 2025, 7:51 PM EDT - 8 months ago

Soleno Therapeutics, Inc. (SLNO) Under Investigation After Scorpion Capital Report Raises Drug Safety Concerns; Investors Urged to Contact Award-Winning Firm, Gibbs Mura

Sep 10, 2025, 5:23 PM EDT - 8 months ago

SLNO Investors Have Opportunity to Join Soleno Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

Sep 10, 2025, 12:57 PM EDT - 8 months ago

Soleno reports death of patient who took genetic disorder treatment, shares fall

Aug 27, 2025, 8:00 AM EDT - 8 months ago

Soleno Therapeutics to Participate in Upcoming September Conferences

Aug 15, 2025, 1:30 PM EDT - 9 months ago

Soleno Under Serious Scrutiny As Short Seller Alleges PWS Drug Is Overpriced, Unsafe

Aug 6, 2025, 4:01 PM EDT - 9 months ago

Soleno Therapeutics Provides Update on U.S. Launch of VYKAT(TM) XR and Reports Second Quarter 2025 Financial Results

Jul 10, 2025, 9:07 AM EDT - 10 months ago

Soleno Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock

Jul 10, 2025, 6:01 AM EDT - 10 months ago

Soleno Therapeutics Announces Proposed $200 Million Public Offering of Common Stock

Night_Owl_Biotech Apr. 24 at 1:57 AM

0 · Reply

Night_Owl_Biotech Apr. 21 at 5:24 PM

1 · Reply

Dragonites Apr. 19 at 3:43 AM

$SLNO The acquisition centers on VYKAT™ XR (formerly DCCR), which was FDA-approved in March 2025 as the first treatment for hyperphagia (extreme hunger) in Prader-Willi syndrome (PWS).

0 · Reply

anachartanalyst Apr. 17 at 2:02 PM

$SLNO https://anachart.com/wp-content/uploads/ana_temp/1776434501_soc-img.jpg

0 · Reply

theoptionsplug Apr. 17 at 4:42 AM

THINGS TO WATCH, FRIDAY, 4/17/26 👁️ $ALLY $BA $SLNO $SPY $QQQ

0 · Reply

InvestKaki Apr. 12 at 12:00 AM

$SPX $NBIX $SLNO $INTC $XCORP https://www.investkaki.com/p/billion-dollar-milestone

0 · Reply

dennismccain Apr. 11 at 3:10 AM

0 · Reply

Ooil Apr. 8 at 9:01 PM

1 · Reply

NasdaqPulse Apr. 8 at 12:38 PM

0 · Reply

BiotechGoldenEra Apr. 8 at 5:51 AM

$SLNO see you at 75

0 · Reply

MikiTrader Apr. 8 at 5:24 AM

$SLNO Yeah, I think people made a really good call. Not just me.

0 · Reply

Night_Owl_Biotech Apr. 8 at 1:13 AM

The 1st attachment shows the collective $NBIX & $SLNO analyst consensus revenue ests as of the morning the M&A exit was announced incl highest analyst est, consensus, lowest analyst est, consensus excl the highest analyst est, & consensus excl both the highest & lowest analyst est. At the bottom we simply add the 2 together for an idea of what NBIX analyst ests may, again may, look like post M&A. We then show a "what-if" NBIX was acquired for a peer 0.35X multiple on 10-year collective consensus just for fun. This may be absurd considering SLNO exited at a 0.15X 10-year multiple. The graph compares the collective NBIX/SLNO 10-year analyst consensus & an assumed gross margin @ 97% (NBIX actual FY25 gross margin = 97%, SLNO = 99%) v. the actual 10-year revenue & gross margin projection prepared by $SGEN when SGEN was acquired for an EV of $42B. SGEN provided a 12 year forecast (projecting peak sales in Year 10). Compare NBIX/SLNO 10 year gross margin (even if too high) to SGEN $XBI $IBB

1 · Reply

Stockanuck Apr. 7 at 6:00 PM

$UNH $SLNO $IBRX $SRPT $LLY Among these big five calls, there was a call option trade with bullish sentiment. It expires in 17 day(s) on April 24, 2026. Parties traded 25 contract(s) at a $300.00 strike. The total cost received by the writing party (or parties) was $45.0K, with a price of $1800.0 per contract. There were 4001 open contracts at this strike prior to today, and today 3958 contract(s) were bought and sold. 9 Health Care Stocks With Whale Alerts In Today's Session https://www.benzinga.com/insights/options/26/04/51687681/9-health-care-stocks-with-whale-alerts-in-todays-session

0 · Reply

Annet_why_net Apr. 7 at 3:53 PM

$OSRH Oops, did I forget to mention the dual-track commercialization? By decoupling the Consumer Wellness launch from the Medical Grade certification, Woori IO can hit the market immediately via Samsung, generating cash flow while clinical trials run in parallel. We don’t have to sit around waiting for FDA approval to start making money. $TERN $SLNO $NVO

1 · Reply

anachartanalyst Apr. 7 at 2:02 PM

$SLNO https://anachart.com/wp-content/uploads/ana_temp/1775570484_soc-img.jpg

0 · Reply

s3q Apr. 7 at 12:49 PM

$SLNO $TERN who’s next $ACAD , $VKTX , $SRPT m&a been very hot

0 · Reply

Trader1141 Apr. 7 at 12:02 PM

$PSTV Floor after FDA news… lol you d@mn right im going to byy some lol $HCAI $DRUG $SILO $SLNO

0 · Reply

PickAlpha Apr. 7 at 11:57 AM

PickAlpha Morning Report - Company News: 2026.04.07 News Analysis - 1/3: Neurocrine Biosciences agreed to acquire Soleno Therapeutics for $53.00 per share in cash via tender offer, with no financing condition and a $95.25 mn termination fee. | View: The binding $53.00 all-cash tender with no financing condition is positive… $NBIX $SLNO $XBI $IBB

0 · Reply

SportTrade Apr. 7 at 11:14 AM

$RYTM Currently commands an Enterprise Value of approximately $5.55 Billion, while $PTN sits at absurd cheap $16.5 Million EV. This means the market is valuing Rhythm’s business operations at 336x the price of Palatin's. Read that again. This valuation gap is mathematically absurd considering Palatin is developing a differentiated oral small molecule targeting the exact same MC4R pathway that the FDA just further de-risked for Rhythm in March 2026. At this current Enterprise Value, the market is essentially pricing Palatin’s clinical-stage obesity IP at near-zero, creating a massive disconnect ahead of a potential transformational year of catalysts starting with imminent IND filing. $SLNO $VKTX

0 · Reply

Stocks_and_Stacks Apr. 7 at 2:19 AM

🚀 Bulls holding strong on April 6 despite geopolitical jitters! 🐂📈 Huge congrats to all the bulls powering through oil spikes and Iran headlines 🔥 green resilience wins again! $FUBO +24% – FuboTV rocketing higher as streaming demand heats up and monthly gains accelerate. $SLNO +32% – Soleno Therapeutics surging on strong momentum in its rare disease pipeline. $AGL +30% – Agilon Health climbing amid healthcare sector rotation and positive earnings momentum. $AEHR +18% – Aehr Test Systems lifting off with semiconductor test equipment demand and AI tailwinds. Epic day stacking gains, bulls 😎 keep riding that wave! 💪 Who else is celebrating today? #TopMovers #BullMarket #Stocks

0 · Reply

DisneyPalaceTrades Apr. 7 at 12:58 AM

Insane alert man, Thanks for calling it early. That @ElevenXProfits is a good bull to Follow bellow, He's been keeping me green in this dead market 💯🔥 Overnighting some $CLIR $XWEL $SLGB $SLNO

0 · Reply

Night_Owl_Biotech Apr. 6 at 11:54 PM

$SLNO M&A enterprise value of $2.44B appears to be priced @ the lowest Year 4 & 10-year revenue multiples in recent history (of course analyst estimates may not be credible). SLNO was acquired for $0.2B more than DAWN's EV. Analysts forecast SLNO to generate roughly $10B more revenues over the next 10 years than $DAWN ? SLNO was acquired for 1.7X FY29 (Year 4) analyst consensus. Centerview cited the lowest peer Year 4 M&A revenue multiple was 2.25X (though an oncology focused trx). See yesterday's post. We'd remind investors SLNO generated 99% gross margins on Vykat sales in FY25. SLNO was acquired for 0.15X 10-year analyst consensus. We recall ZGNX & SWTX exiting at the lowest 10-year multiples of 0.25 & 0.26X, respectively. Most peer M&A exits are priced @ 0.30-0.40X 10-year revenues per the acquiree mgmt/BOD $NBIX closed at 3.1X. If SLNO FY29 consensus is credible then, because no stock was issued, this s/b quite accretive to NBIX shareholders This is not investment advice $XBI $IBB

2 · Reply

Market Cap	2.73B
Revenue (ttm)	190.41M
Net Income (ttm)	20.89M
EPS (ttm)	N/A
PE Ratio	229.35
Forward PE	14.39
Profit Margin	10.97%
Debt to Equity Ratio	0.11

Volume	3,281,900
Avg Vol	3,821,086
Day's Range	N/A - N/A
Shares Out	51.62M
Stochastic %K	54%
Beta	-2.81
Analysts	Hold
Price Target	$53.00